By continuing, you agree to LoansJagat's Credit Report Terms of Use, Terms and Conditions, Privacy Policy, and authorize contact via Call, SMS, Email, or WhatsApp
Disclaimer: The information published on LoansJagat is intended for general informational and educational purposes only and should not be considered financial, legal, or investment advice. Interest rates, loan terms, statistics, and other data may change over time and may vary by lender or source. Please verify the latest information and consult a qualified financial advisor or the respective Bank/NBFC before making any financial decisions.
Subscribe Now
About the author
LoansJagat Team
‘Simplify Finance for Everyone.’ This is the common goal of our team, as we try to explain any topic with relatable examples. From personal to business finance, managing EMIs to becoming debt-free, we do extensive research on each and every parameter, so you don’t have to. Scroll up and have a look at what 15+ years of experience in the BFSI sector looks like.
Related Blog Post
Simplify All Your Loans Into One Affordable EMI
Customers Served
Debt Consolidated
1200+ Reviews
Locations in India
Club all Loans & Credit Card Bills into Single EMI
Quick Apply Loan
Consolidate your debts into one easy EMI.
Takes less than 2 minutes. No paperwork.
10 Lakhs+
Trusted Customers
2000 Cr+
Loans Disbursed
4.7/5
Google Reviews
50+
Banks & NBFCs Offers
Other services mentioned in this article
David Martin, a seasoned investor, had always kept a keen eye on emerging biotech companies. One such company that piqued his interest was BioNano Genomics Inc. (BNGOW). Over the past year, BNGOW's stock price experienced significant volatility, reaching a 52-week high of $0.488 and falling to a low of $0.0036 on August 17, 2023.
BioNano Genomics' second-quarter 2024 revenues fell from the previously projected $7.9 million to $8.9 million, to between $6.5 million and $6.8 million. Investors became concerned about the business's financial health as a result of this change.
David pointed out that the company's price-to-earnings (P/E) ratio was negative and its market capitalisation was unavailable, both of which suggested persistent financial difficulties. Despite these problems, the research community continued to see promise in BioNano's Saphyr device, which is intended for ultra-sensitive genome analysis.
David saw opportunities as well as risks in the stock's performance. He made the decision to keep a careful eye on BNGOW because he saw it as a potentially lucrative speculative investment if the company's technology became more widely used. He was careful of the stock's inherent volatility and financial risks, yet he continued to exercise caution.
BNGOW refers to the warrants issued by BioNano Genomics Inc., a life sciences instrumentation company specialising in genome analysis. These warrants grant holders the right to purchase common shares of BioNano Genomics at a specified price before the warrants' expiration date.
Note: Given BioNano Genomics' substantial losses and the significant decline in the value of its warrants, potential investors should exercise caution. It's essential to conduct thorough research and consider consulting financial advisors before making investment decisions related to BNGOW or the company's common shares.
Factor | Impact on BNGOW Stocks |
Revenue Fluctuations | BioNano Genomics has experienced variability in its revenue streams. In the third quarter of 2024, the company reported revenues between $6.5 million and $6.8 million, a decrease from the earlier projected range of $7.9 million to $8.9 million. This decline was primarily due to a reduction in clinical services, highlighting the impact of operational changes on financial outcomes. |
Cash Reserves and Funding | BioNano has over $23.3 million in cash on hand at the end of Q3 2024. In May 2024, the business raised $18 million through a private placement to strengthen its finances, mostly to pay off a previous convertible debt. Nevertheless, the company's market value has dropped significantly despite all of these measures, indicating persistent financial difficulties. |
Stock Name | Market Cap (₹ Cr) | P/E Ratio | Dividend Yield (%) | 1-Year Return (%) |
BioNano Genomics Inc | 12.25M USD | - |
Disclaimer: Please note that stock data provided in the table is sourced from Google Finance. We recommend verifying any financial information through additional trusted resources before making any investment decisions.
Investing in BNGOW warrants, associated with BioNano Genomics Inc., requires careful consideration due to several key factors:
Risk Factor | Impact |
Debt Obligations and Liquidity Concerns | Bionano amended its senior secured convertible debentures in December 2024, lowering short-term financial requirements and postponing payments. The amendment mandates the issuance of 5,000,000 shares of common stock and reduces the conversion price from $2.00 to $0.27. Although these adjustments aim to increase liquidity, they also highlight current financial difficulties. |
Stock Price Volatility and Delisting Risk | The stock has seen significant volatility with a 92% drop in the last year. To meet the Nasdaq's minimum bid price requirement of $1.00 per share, the business suggested a reverse stock split in December 2024, underscoring the possibility of delisting if the stock price stays low. |
Risk Factor | Detail | Before | After (April 2025) | Impact on David |
Initial Investment | Number of shares bought at $2.00 | 10,000 shares × $2.00 |
Ownership: 10,000 / 50M = 0.02%
Ownership: 10,000 / 55M = 0.01818%
- 9% drop in ownership %
Operational Cuts
203 layoffs, exit from some services
Full-service model
Focused on OGM tech
May reduce revenue diversity.
Product Adoption and Technological Advances | Despite financial setbacks, BioNano's Optical Genome Mapping (OGM) technology has shown promise. A study published in the Blood Cancer Journal highlighted its effectiveness in identifying gene rearrangements in multiple myeloma, potentially broadening its application in blood cancer diagnostics. Additionally, the company reported growth in its OGM installed base and the acceptance of a Category 1 Current Procedural Terminology code by the American Medical Association, indicating progress in product adoption. |
Stock Performance | BioNano Genomics' stock has faced significant volatility, reaching a 52-week low of $0.20 in November 2024. Over the past year, the stock value has declined by approximately 85.86%, reflecting investor scepticism regarding the company's ability to overcome its challenges. |
Analyst Downgrades | Reflecting concerns over the company's financial health and operational challenges, BTIG downgraded BioNano Genomics from Buy to Neutral in September 2024. This downgrade highlights the market's cautious stance on the company's prospects. |
-
-55.84 1Y |
Operational Challenges | In 2024, Bionano laid off about 203 workers to reduce expenses and streamline operations. Additionally, to focus on its Optical Genome Mapping (OGM) technologies, the company has begun to phase out some testing services, which may have an effect on income streams. |
Profitability Concerns | Even though the number of Saphyr systems it has installed has increased, Bionano has not turned a profit and is not planning on doing so until at least 2026. Concerns over the company's financial sustainability are raised by the significant operating losses it continues to experience. |
Shareholder Dilution | Bionano has diluted shareholder value by issuing more shares to finance activities. As the business looks for funding to support its expansion plans, this practice might persist and have an impact on the equity held by current shareholders. |
—
$20,000 invested |
Stock Price Drop (92%) | Current share price after 92% drop | $2.00 per share | $0.16 per share | Value drops to $1,600 |
Reverse Stock Split | Proposed 1-for-10 split to meet Nasdaq compliance | 10,000 shares | 1,000 shares (at $1.60 post-split) | No change in value, but reduced share liquidity |
Dilution (5M shares issued) | Increase in total shares from 50M to 55M |
*T&C Apply
Profitability Delay
Not expected until at least 2026 |
Profit expected soon |
No profit until 2026 |
Low confidence in short-term recovery |
Metric | Before (Early 2024) | After (April 2025) |
Shares Owned | 10,000 | 1,000 (after 1:10 split) |
Share Price | $2.00 | $1.60 (adjusted post-split) |
Investment Value | $20,000 | $1,600 |
Unrealised Loss | — | $18,400 |
Bionano Genomics Inc. (BNGOW), a biotechnology company situated in the United States, is mostly traded on the NASDAQ as of April 2025. At the moment, BNGOW stock is not directly traded on Indian markets like the BSE or NSE. Generally speaking, Indian investors who are interested in BNGOW would have to use platforms that allow trading in U.S. stocks to access international markets.
In regard to BNGOW stock's prospects for the future, it's important to remember that the business is currently dealing with serious financial difficulties. With a 100% possibility of going bankrupt in the next two fiscal years, Bionano Genomics is likely to experience financial difficulties. In order to manage its financial obligations, the corporation has also issued convertible debentures and reported significant net losses. All of these factors suggest that investing in BNGOW carries a significant level of risk.
Though there is hope for expansion in the Indian stock market, especially in areas like utilities and infrastructure, BNGOW's performance is primarily affected by changes in the biotechnology industry in the United States. Therefore, before thinking about investing in BNGOW, Indian investors should proceed with care and do thorough research.
An Indian investor, Rohan, utilises a global investment platform that gives him access to U.S. stocks and is drawn to biotech businesses.
In May 2025, Rohan decides to invest ₹1,00,000 in BNGOW stock.
Assume the exchange rate is ₹83/USD, so:
BNGOW is trading at $0.20 per share (highly volatile and speculative).
Rohan buys: $1,204 ÷ $0.20 = 6,020 shares of BNGOW.
Outcomes by Mid-2026:
Scenario | Share Price | Investment Value (USD) | Value in INR (@₹85/USD) | Gain/Loss in ₹ |
Optimistic Recovery | $0.50 | 6,020 × $0.50 = $3,010 | ₹2,55,850 | +₹1,55,850 |
Bankruptcy or Fall | $0.05 | 6,020 × $0.05 = $301 | ₹25,585 | −₹74,415 |
A highly speculative stock with significant financial volatility is BNGOW. The probability of the company going bankrupt in the upcoming two fiscal years is 100%. Investors need to be ready for the possibility that they could lose all of their money.
In view of the company's current financial difficulties and low profitability, BNGOW might not produce profits right
away. To realise any gains, investors should be prepared to keep the stock for a long time—possibly years.
BNGOW operates in the genomics and biotechnology industry, focusing on structural variation analysis through its Saphyr system. Investors interested in this sector may consider BNGOW as a speculative addition to their portfolio.
BNGOW has experienced significant stock price fluctuations, with a 52-week range from $0.31 to $3.24. Investors should be prepared for continued volatility and the possibility of substantial price swings.
BNGOW is primarily traded on the NASDAQ and is not directly available on Indian exchanges. Indian investors would need to access international markets through platforms that facilitate trading in U.S. equities.
For example:
In April 2025, Aman, a 30-year-old Indian investor with a high-risk tolerance, invests $1,000 USD (about ₹83,000) in BNGOW for $0.25 per share. He purchases 4,000 shares.
Aman accepts the 100% bankruptcy risk for potential 4x returns, knowing this is a speculative biotech bet.
Since the stock is traded on the NASDAQ and not directly available on Indian exchanges, investing in Bionano Genomics Inc. (BNGOW) from India requires several processes. Here's how to go about it:
To invest in BNGOW, you'll need to open an international trading account with a brokerage that offers access to U.S. stocks. Platforms like Angel One facilitate this process for Indian investors. The account opening involves completing KYC verification and funding the account in U.S. dollars.
Transfer funds to your foreign trading account from your Indian bank account. Keep in mind that your bank may impose different remittance fees. The money usually takes one to four business days to appear in your trading account.
Once your account is funded, use the trading platform to search for BNGOW. You can enter "BNGOW" in the search bar to locate the stock. Review the stock's details, including its current price and performance metrics.
Decide how much you want to invest in BNGOW, then use your trading platform to place a buy order. Make sure you are aware of the various order types (such as market or limit orders) and any related costs.
After purchasing, regularly monitor your investment's performance. Keep an eye on any news or developments related to Bionano Genomics Inc. that might affect the stock's value.
Investing in Bionano Genomics Inc. (BNGOW) is highly speculative and only suitable for high-risk tolerance investors. The company has severe financial problems, including unprofitable margins, operating losses, and a high chance of bankruptcy within the next two fiscal years.
The ratings from analysts have generally been neutral with some companies degrading the stock due to financial concerns of the company. Bearing these issues in mind, investors must exercise caution and consider the gigantic risks before they make any investment.
Q. What is the market cap of Bionano Genomics Inc Warrant (BNGOW)?
As of August 17, 2023, at 16:00 EDT, the share price of Bionano Genomics Inc. Warrant (BNGOW) is $0.00 (NASDAQ). Over the past three years, the Bionano Genomics Inc. Warrant (BNGOW) has returned -75.22%.
Q. What is the total promoter pledging in the Bionano Genomics Inc. Warrant (BNGOW)?
The Bionano Genomics Inc. Warrant (BNGOW) does not contain a promoter pledge.
Q. Is the Bionano Genomics Inc. Warrant (BNGOW) profitable?
The BNGOW warrant is not profitable at the moment unless the stock price of Bionano Genomics increases considerably over the exercise price of $0.252. Considering that the company has financial difficulties, its future profitability is doubtful.
